603259 药明康德
2025/06 - 中期
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入20,799,28220.64%39,241,43140,340,80739,354,77822,902,385
减:营业总成本14,014,55614.84%27,342,26828,708,59129,800,81118,574,516
    其中:营业成本11,554,12410.52%22,964,51523,728,80024,677,21714,592,256
               财务费用206,204-134.18%(786,684)(338,119)(247,968)84,082
               资产减值损失(321,420)-2,916.35%(1,236,258)(156,509)(175,951)(33,056)
公允价值变动收益(182,183)82.94%186,958(37,809)770,079(93,387)
投资收益3,669,21316,295.49%604,162233,849187,9491,356,269
    其中:对联营企业和合营企业的投资收益240,269115.20%245,065(67,560)(46,271)(117,290)
营业利润9,931,11895.55%11,580,17511,872,28610,652,2496,037,725
利润总额9,907,41796.20%11,539,81211,831,99110,618,4766,015,609
减:所得税费用1,247,06862.23%1,972,0722,131,7311,715,866879,662
净利润8,660,348102.30%9,567,7409,700,2608,902,6115,135,947
减:非控股权益99,465142.46%117,43193,51188,89838,792
股东净利润8,560,883101.92%9,450,3089,606,7498,813,7135,097,155

市场价值指针
每股收益 (元) *3.010106.16%3.2803.2703.0101.750
每股派息 (元) *0.700--0.9820.9900.8930.517
每股净资产 (元) *20.85911.01%20.30218.57015.73713.020
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容